Intergroupe Francophone De Cancerologie Thoracique

This study is testing whether a new drug called tarlatamab works better than standard chemotherapy for people with advanced neuroendocrine carcinoma that has worsened after initial treatment. It's a large, late-stage trial that will measure if the drug helps patients live longer …

This study is testing a new drug called ivonescimab for people with pleural mesothelioma whose cancer has grown again after receiving standard immunotherapy and chemotherapy. About 38 participants will receive the drug every three weeks for up to two years. The main goal is to se…

This study is testing whether the drug tepotinib works better than standard treatments for people with advanced non-small cell lung cancer that has a specific genetic change called a MET exon 14 mutation. The trial is for patients whose cancer has worsened after at least one prio…

This study is testing a two-step treatment for people with stage III non-small cell lung cancer who are elderly or have other health conditions that make standard aggressive treatments too risky. It combines immunotherapy and chemotherapy first, followed by a shorter course of ra…